Correlation Between Biotechnology Fund and Sp Midcap

Can any of the company-specific risk be diversified away by investing in both Biotechnology Fund and Sp Midcap at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Biotechnology Fund and Sp Midcap into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Biotechnology Fund Class and Sp Midcap 400, you can compare the effects of market volatilities on Biotechnology Fund and Sp Midcap and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Biotechnology Fund with a short position of Sp Midcap. Check out your portfolio center. Please also check ongoing floating volatility patterns of Biotechnology Fund and Sp Midcap.

Diversification Opportunities for Biotechnology Fund and Sp Midcap

-0.12

Correlation Coefficient

Biotechnology Fund  Sp Midcap

Good diversification

The 3 months correlation between Biotechnology and RYBHX is -0.12. Overlapping area represents the amount of risk that can be diversified away by holding Biotechnology Fund Class and Sp Midcap 400 in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sp Midcap 400 and Biotechnology Fund is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Biotechnology Fund Class are associated (or correlated) with Sp Midcap. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sp Midcap 400 has no effect on the direction of Biotechnology Fund i.e., Biotechnology Fund and Sp Midcap go up and down completely randomly.

Pair Corralation between Biotechnology Fund and Sp Midcap

Assuming the 90 days horizon Biotechnology Fund Class is expected to under-perform the Sp Midcap. In addition to that, Biotechnology Fund is 1.02 times more volatile than Sp Midcap 400. It trades about -0.36 of its total potential returns per unit of risk. Sp Midcap 400 is currently generating about -0.21 per unit of volatility. If you would invest  5,923  in Sp Midcap 400 on January 29, 2024 and sell it today you would lose (255.00) from holding Sp Midcap 400 or give up 4.31% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Biotechnology Fund Class  vs.  Sp Midcap 400

Biotechnology Fund Class

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Biotechnology Fund Class has generated negative risk-adjusted returns adding no value to fund investors. In spite of latest weak performance, the Fund's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the fund investors.

Sp Midcap 400

Risk-Adjusted Performance

14 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Sp Midcap 400 are ranked lower than 14 (%) of all funds and portfolios of funds over the last 90 days. In spite of fairly weak technical indicators, Sp Midcap showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Biotechnology Fund and Sp Midcap

The main advantage of trading using opposite Biotechnology Fund and Sp Midcap positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Biotechnology Fund position performs unexpectedly, Sp Midcap can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sp Midcap will offset losses from the drop in Sp Midcap's long position.

The idea behind Biotechnology Fund Class and Sp Midcap 400 pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.